Cerenome picks XiFin for billing services on CNSide platform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Cerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide Platform
August 6, 2026 7:30 AM EDTHOUSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (Cerenome or the Company), announced today that it has selected XiFin, Inc. (XiFin), a market leader in artificial intelligence (AI)-driven revenue cycle management (RCM) for diagnostic providers, to provide billing and clearinghouse services for the CNSide® Cerebrospinal Fluid (CSF) Assay Platform. The Company expects to commence billing through the XiFin platform during the third quarter of 2026, including submission of the accumulated backlog of previously performed CNSide® tests.
XiFin Empower RCM provides end-to-end revenue cycle infrastructure purpose-built for... More
